Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEWARK, DE--(Marketwired - Jun 17, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, amended its...
-
Copenhagen, 2014-06-17 10:17 CEST (GLOBE NEWSWIRE) -- Press Release No. 5/2014 Lyxumia® (lixisenatide): Results from an 8-week head-to-head study versus liraglutide support...
-
København, 2014-06-17 10:17 CEST (GLOBE NEWSWIRE) -- Pressemeddelelse Nr. 5/2014 Lyxumia® (lixisenatid): Resultater fra et 8-ugers studie op imod liraglutid understøtter lixisenatids...
-
Copenhagen, 2014-06-17 09:07 CEST (GLOBE NEWSWIRE) -- New data on novel glucagon analogue, ZP-GA-1 further support its broad potential in the treatment of diabetes both as a ready-to-use...
-
København, 2014-06-17 09:07 CEST (GLOBE NEWSWIRE) -- Nye data på glukagon-analogen, ZP-GA-1 underbygger yderligere dens brede potentiale inden for behandling af diabetes både i form af en pen...
-
Manufacturing of MACI in Denmark to be discontinued Sales of MACI in Europe, representing 1% of revenues in 2014, temporarily ceased U.S. action plan implemented to optimize R&D,...
-
ANN ARBOR, Mich., June 15, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
-
Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) - Meta-analysis of three late-stage trials in people with type 2 diabetes shows...
-
Sanofi annonce des résultats positifs de phase 3 pour Toujeo®(insuline glargine [origine ADNr] injectable, 300 U/ml) - Une méta-analyse des résultats de trois essais de phase 3 chez des personnes...
-
Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) - Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases...